|Bid||20.16 x 1100|
|Ask||0.00 x 1400|
|Day's Range||21.71 - 22.43|
|52 Week Range||20.21 - 31.88|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.50|
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the closing of its initial public offering of 9,109,725 shares of common stock at a public offering price of $17.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,188,225 additional shares of common stock. All of the shares of common stock were offered by Personalis. Personalis estimates net proceeds from the offering to be approximately $140.8 million, after deducting underwriting discounts and commissions and estimated offering expenses.
Data analytics in the biotech realm comes in the form of genomic sequencing – the process of determining the complete DNA sequence of an organism's genome, which helps in developing personalized and targeted ...
Personalis, Inc., a leader in advanced genomics for cancer, today announced the pricing of its initial public offering of 7,921,500 shares of common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by Personalis. In addition, Personalis has granted the underwriters a 30-day option to purchase up to an additional 1,188,225 shares of common stock from Personalis at the public offering price less underwriting discounts and commissions.
For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . The IPO dates below are expected but not confirmed. Stoke Therapeutics, Inc. (STOK) will issue 6.7 million shares between ...